EyePoint Pharmaceuticals posted Q2 2026 results and outlined recent corporate moves as it prepares for key clinical milestones. The company named a chief strate

EyePoint Pharmaceuticals posted Q2 2026 results and outlined recent corporate moves as it prepares for key clinical milestones. The company named a chief strategic science officer and completed Phase 3 enrollment for DURAVYU in DME, with topline data due in late 2027.